From Coffee to Collaboration: Bringing ASCEND to Life with AMGEN
How ASCEND came to be and the instrumental role Amgen played to help shape this revolutionary platform for preclinical pharmaceutical research
How ASCEND came to be and the instrumental role Amgen played to help shape this revolutionary platform for preclinical pharmaceutical research
Provides analysis of artificial intelligence in drug discovery data, including startup growth and funding.
New technologies are flipping traditional antibody-based assays on their heads. These immunoassays are quicker, more sensitive, can be conducted high-throughput, and require minimal sample. It’s an exciting time to be a bench scientist!
Phenomic AI conducts high-throughput phenotypic screens using artificial intelligence to analyze the resulting microscopy images. I sat down with three Phenomic AI biologists, Allison Nixon, Max London, and Elizabeth Koch, to learn more about the company and it’s technology.
Cyclica predicts a drug’s polypharmacology to provide insights into adverse effects, repurposing, and more. Learn polypharmacology’s challenges and opportunities, how AI is necessary—but not sufficient—to address them, and opportunities in drug discovery driven by computing and genomics advances.
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Nick Lynch of the Pistoia Alliance, a global nonprofit community of life science stakeholders that works to lower barriers to R&D innovation. A new area of strategic focus is AI, which Nick oversees.
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Lucas Siow of ProteinQure on how they’re combining quantum computing, reinforcement learning, and molecular simulations to design protein-based therapeutics.
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Regina Barzilay, prolific machine learning researcher, on automating small molecule discovery and synthesis.
For this episode of the Artificial Intelligence in Drug Discovery podcast, I speak with Tim Guilliams and David Brown of Healx. Healx uses AI to repurpose existing drugs for rare diseases.